Akebia Therapeutics Inc. (AKBA)
Akebia Therapeutics (AKBA) Loses 39.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Akebia Therapeutics (AKBA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Akebia Therapeutics, Inc. (AKBA) Q3 2025 Earnings Call Transcript
Akebia Therapeutics, Inc. ( AKBA ) Q3 2025 Earnings Call November 10, 2025 8:00 AM EST Company Participants Mercedes Carrasco - Senior Director of Investor & Corporate Communications John Butler - CEO, President & Director Nicholas Grund - Senior VP & Chief Commercial Officer Erik Ostrowski - Chief Business Officer, Senior VP, CFO & Treasurer Conference Call Participants Roanna Clarissa Ruiz - Leerink Partners LLC, Research Division Andrew Kassin - BTIG, LLC, Research Division Matthew Caufield - H.C. Wainwright & Co, LLC, Research Division Jiale Song - Jefferies LLC, Research Division Presentation Operator Good day, and thank you for standing by.
5 Small Drug Stocks to Buy as the Industry Shows Some Recovery
Innovation is at its peak in the Zacks Medical-Drugs industry. AKBA, IRWD, PYXS, CRDL and PSTV may prove to be good additions to one's portfolio.
Akebia Therapeutics, Inc. (AKBA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 8:00 AM EDT Company Participants Erik Ostrowski - Chief Business Officer, Senior VP, CFO & Treasurer Nicholas Grund - Senior VP & Chief Commercial Officer Presentation Unknown Analyst Good morning and thank you for joining us here today at the Wells Fargo Healthcare Conference. I'm joined with the team from Akebia today.
Akebia Therapeutics, Inc. (AKBA) Q2 2025 Earnings Call Transcript
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Erik John Ostrowski - Chief Business Officer, Senior VP, CFO & Treasurer John P. Butler - CEO, President & Director Mercedes Carrasco - Senior Director of Investor & Corporate Communications Nicholas Grund - Senior VP & Chief Commercial Officer Conference Call Participants Julian Reed Harrison - BTIG, LLC, Research Division Mazahir Lukman Alimohamed - Leerink Partners LLC, Research Division Roger Song - Jefferies LLC, Research Division Operator Good day and thank you for standing by.
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q2
Akebia Therapeutics (AKBA) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.04 per share a year ago.
Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year?
Here is how Akebia Therapeutics (AKBA) and Alignment Healthcare (ALHC) have performed compared to their sector so far this year.
Akebia Therapeutics (AKBA) Upgraded to Strong Buy: Here's What You Should Know
Akebia Therapeutics (AKBA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year?
Here is how Akebia Therapeutics (AKBA) and ResMed (RMD) have performed compared to their sector so far this year.
Akebia Therapeutics, Inc. (AKBA) Q1 2025 Earnings Call Transcript
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director of Investor Relations John Butler - Chief Executive Officer Nick Grund - Chief Commercial Officer Erik Ostrowski - Chief Financial and Chief Business Officer Conference Call Participants Roanna Ruiz - Leerink Partners Roger Song - Jefferies Allison Bratzel - Piper Sandler Les Siloski - Truist Securities Operator Good day and thank you for standing by. Welcome to Akebia's First Quarter 2025 Financial Results Call.
Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates
Akebia Therapeutics (AKBA) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.09 per share a year ago.
Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy?
Akebia Therapeutics (AKBA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
